Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2015
Summary
Global Markets Direct’s, ‘Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H2 2015’, provides an overview of the Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Overview 6
Therapeutics Development 7
Pipeline Products for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview 7
Pipeline Products for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis 8
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics under Development by Companies 9
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Products under Development by Companies 12
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Companies Involved in Therapeutics Development 13
Human Stem Cells Institute 13
Lacer, S.A. 14
Nuo Therapeutics, Inc. 15
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
ALD-201 - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Disease and Central Nervous System Disorders - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
LA-419 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Oligonucleotides for Ischemic Heart Disease and Duchenne Muscular Dystrophy - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Protein for Cardiovascular Diseases - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Recent Pipeline Updates 28
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 30
Disclaimer 31
List Of Tables
Number of Products under Development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), H2 2015 7
Number of Products under Development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 10
Comparative Analysis by Early Stage Development, H2 2015 11
Products under Development by Companies, H2 2015 12
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Human Stem Cells Institute, H2 2015 13
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lacer, S.A., H2 2015 14
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Nuo Therapeutics, Inc., H2 2015 15
Assessment by Monotherapy Products, H2 2015 16
Number of Products by Stage and Target, H2 2015 17
Number of Products by Stage and Mechanism of Action, H2 2015 18
Number of Products by Stage and Route of Administration, H2 2015 20
Number of Products by Stage and Molecule Type, H2 2015 22
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Therapeutics - Recent Pipeline Updates, H2 2015 28
Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H2 2015 29
List Of Figures
Number of Products under Development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease), H2 2015 7
Number of Products under Development for Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Comparative Analysis by Clinical Stage Development, H2 2015 10
Assessment by Monotherapy Products, H2 2015 16
Number of Products by Top 10 Routes of Administration, H2 2015 19
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 19
Number of Products by Top 10 Molecule Types, H2 2015 21
Number of Products by Stage and Top 10 Molecule Types, H2 2015 21
